Prevention of lysosomal storage diseases and derivation of2

34
Prevention of Lysosomal Storage Diseases and Derivation of Mutant StemCell Lines by Preimplantation Genetic Diagnosis. Gheona Altarescu, Rachel Beeri, Rachel Eiges, Silvina Epsztejn-Litman, Talia Eldar-Geva, Deborah Elstein, Ari Zimran, Ehud J.Margalioth, Ephrat Levy-Lahad, and Paul Renbaum. Tatiana Gil Franco Paula E Montoya Medicine students Molecular Biology

Transcript of Prevention of lysosomal storage diseases and derivation of2

Page 1: Prevention of lysosomal storage diseases and derivation of2

Prevention of Lysosomal Storage Diseases and Derivation of Mutant StemCell Lines by Preimplantation Genetic Diagnosis.

Gheona Altarescu, Rachel Beeri, Rachel Eiges, Silvina Epsztejn-Litman, Talia Eldar-Geva, Deborah Elstein, Ari Zimran, Ehud J.Margalioth, Ephrat Levy-Lahad, and Paul Renbaum.

Tatiana Gil Franco Paula E Montoya

Medicine students Molecular Biology

Page 2: Prevention of lysosomal storage diseases and derivation of2

INTRUDUCTION Preimplantation genetic diagnosis( PGD) is a great tool for avoiding the transmission for genetic diseases to descendants. This is a challenging method because have analyze de disorder in a single cell , and have to build protocols for each specific mutation.Is necessarily that give the results in a short time, that can used in testing two or more indications at once and accuracy rates approaching 100%; to get this, use information of genomic DNA from

family and polar bodies , how give maternal autosomal dominant.

Page 3: Prevention of lysosomal storage diseases and derivation of2

Stem cells

• Undifferentiated cell capable of self-renewal and differentiate into more specialized cells.

Page 4: Prevention of lysosomal storage diseases and derivation of2

Stem cells

• Self-renewal: the ability to go through numerous cycles of cell division while maintaining the undifferentiated state.

• Potency: the capacity to differentiate into specialized cell types.

Page 5: Prevention of lysosomal storage diseases and derivation of2

Types of stem cells

1. Embryonic stem cells, which are isolated from the inner cell mass of blastocysts

2. Adult stem cells, which are found in various tissues.

Page 6: Prevention of lysosomal storage diseases and derivation of2

Lysosomes

Page 7: Prevention of lysosomal storage diseases and derivation of2

lysosomesClassification

Over 60 lysosomal enzymes are known. There is a hydrolyse for each type of biological molecule: •Peptidases – hydrolyse proteins•DNAases – hydrolyse DNA•RNAases – hydrolyse RNA•Lipases – hydrolyse lipids•Phosphatases – hydrolyse phosphates•Glucosidases – hydrolyse glycogen•Carboxylases - hydrolyse carboxyl groups•Sulphatases – hydrolyse sulphate

• Primary: those that contain enzymes solon.

•  Secondary: besides containing enzymes, also digestion materials.

Page 8: Prevention of lysosomal storage diseases and derivation of2

LSD

• Lysosomal storage diseases are genetic disorders in which a genetic mutation affects the activity of one or more of the acid hydrolases. In such diseases, the normal metabolism of specific macromolecules is blocked and the macromolecules accumulate inside the lysosomes, causing severe physiological damage or deformity.

Page 9: Prevention of lysosomal storage diseases and derivation of2
Page 10: Prevention of lysosomal storage diseases and derivation of2

PGD

Preimplantation genetic testing is a technique used to identify genetic defects in embryos created through in vitro fertilization (IVF) before pregnancy. Preimplantation genetic diagnosis (PGD) refers specifically to when one or both genetic parents has a known genetic abnormality and testing is performed on an embryo to determine if it also carries a genetic abnormality.

Page 11: Prevention of lysosomal storage diseases and derivation of2
Page 12: Prevention of lysosomal storage diseases and derivation of2

Objective • Present the strategy and outcome of PGD for four

lysosomal storage disorders ( TSD,GD,FD,HS) with the purpose of avoiding the transmission for genetic diseases and termination of pregnancy in couples at risk of transmitting of these disorders.

Page 13: Prevention of lysosomal storage diseases and derivation of2

Materiales y Métodos •Tay Sachs

Double carrier

4 (PGD)-5(prenatal diagnosis)

Page 14: Prevention of lysosomal storage diseases and derivation of2

•Gaucher

Familia 2 : heterocigoto /mutación paternaFamilia 3:mujer GS/marido mutación 84GG -50%

Page 15: Prevention of lysosomal storage diseases and derivation of2

•Fabry : 2 parejas : hombre enfermo de fabry azoospermia no obstructiva en una pareja hombres serán sanos –mujeres portadoras (ligado al X) no implantar portadores

•Síndrome de Hunter

1 y 2 : hermanas –CVS3: mujer –análisis prenatal –interrupción –doble mutación

Page 16: Prevention of lysosomal storage diseases and derivation of2

IVF- estimulación ovárica, recuperación del ovocito , fertilización y biopsia

congelados-descongelados: Valerato de estradiol oral (Estrofem 4-8mg al día) y vaginal Utrogestan (progesterona micronizada 900 mg / día). Cuerpo polar y blastómero

Page 17: Prevention of lysosomal storage diseases and derivation of2

Análisis Molecular

• Se extrajo el ADN de las células de sangre periférica ( parejas, niños afectados y familiares de primer grado ).

• Para cada enfermedad: Marcadores polimórficos de microsatélites que rodean el gen

enfermo se identificaron y los marcadores informativos usados, se crearon haplotipos para cada familia.

Estos marcadores y las mutaciones familiares se usaron para el desarrollo de ensayos múltiples de una sola célula.

Una reacción de PCR múltiple se utiliza . Sólo las muestras que fueron informativas para un mínimo de tres

marcadores polimórficos se consideraron para el diagnóstico. Precauciones estrictas para evitar cualquier foco de contaminación.

Page 18: Prevention of lysosomal storage diseases and derivation of2
Page 19: Prevention of lysosomal storage diseases and derivation of2
Page 20: Prevention of lysosomal storage diseases and derivation of2

Derivación de líneas y mantenimiento • Derivación y mantenimiento de indiferenciados Shaare

Zedek (SZ) Hunter y células de Gaucher se llevaron a cabo de acuerdo con protocolos aplican rutinariamente en blastocitos diagnosticados como mutante

Page 21: Prevention of lysosomal storage diseases and derivation of2

Tabla 3

Page 22: Prevention of lysosomal storage diseases and derivation of2

Tabla 3

Page 23: Prevention of lysosomal storage diseases and derivation of2

Tabla 4• De los 28 embriones, se

obtuvieron dos líneas de células madre embrionarias humanas (HESC).

• Una de un embrión mutante Hunter hembra.

• Otra de compuestos heterocigotos 84GG/N370S para la enfermedad de Gaucher.

Page 24: Prevention of lysosomal storage diseases and derivation of2

Figura 1

Page 25: Prevention of lysosomal storage diseases and derivation of2

Figura 1 (A) Electroforesis: método de laboratorio en el que se utiliza una corriente eléctrica controlada con la finalidad de separar biomoleculas según su tamaño y carga eléctrica a través de una matriz gelatinosa. (1937)

Estas nuevas líneas presentan características típicas de células madre embrionarias humanas, que expresan un panel de marcadores no diferenciados, como NANOG, Oct4, Sox2, y REX

Page 26: Prevention of lysosomal storage diseases and derivation of2

Figura 1 (b)• Análisis cromosómico

por tinción de Giemsa, llevado a cabo en metafase.

• Mostró un cariotipo normal, 46XX humano para la línea celular Hunter y 46XY para la línea de Gaucher.

Page 27: Prevention of lysosomal storage diseases and derivation of2

Figura 1 (c) • Se observaron colonias de

células madre embrionarias humanas (HESC) y cuerpos embrioides.

• HESC: células que poseen la capacidad de dividirse por largos periodos, se pueden diferenciar en las células de distintos linajes. (Pluripotentenciales).

• Cuerpos embrioides: son agregaciones espontáneas de HESC que se producen in vitro después de ser cultivadas en un medio carente del FACTOR INHIBIDOR LEUCÉMICO.

Page 28: Prevention of lysosomal storage diseases and derivation of2

Discussion

AUTHOR OPINIONAGREE OR DISAGREE

K. Toyooka

In the second couple there was no known infertility but since more than half of female carriers of Fabry disease develop symptoms during life [22], they preferred medical sex

election for males.

G. L. Harton, M. De Rycke, F. Fiorentino.

Since PGD was first performed in 1991, by using different strategies, the technique has become very accurate with a misdiagnosis rate of less than 1% [26].

Page 29: Prevention of lysosomal storage diseases and derivation of2

DiscussionAUTOR OPINION

AGREE OR DISAGREE

P. Kozlowski, A. Knippel, and R. Stressig.

Both of these invasive methods are accompanied by a small risk of abortion due to the procedure [28].

A. Ribner, G. Altarescu, A. Zimran, and

D. Elstein.

One Gaucher stem cell line was derived from mutant embryos caring 84GG and N370S mutations is of particular of interest due to recent evidence of correlations between Parkinson disease and Gaucher [29].

Page 30: Prevention of lysosomal storage diseases and derivation of2

Conclusions

The article was very interesting because it

shows us the statistics of a prevention

method for orphan and serious diseases, such

as lysosomal storage diseases.

It is also interesting to note the good prognosis that has this therapy in the prevention of the children’s birth with mutations.

Page 31: Prevention of lysosomal storage diseases and derivation of2

ConclusionsIt is satisfying to know that PGD is a procedure in

which is cared the embryo’s stability and also is

forecasted the future mutations in genes of the

embryo.

Despite being a technique in which is risked the lives of many embryos, is a procedure whose purpose is to provide better quality for babies born.

Page 32: Prevention of lysosomal storage diseases and derivation of2

Concept map

Page 33: Prevention of lysosomal storage diseases and derivation of2

MAPA PAULA

Page 34: Prevention of lysosomal storage diseases and derivation of2

GRACIAS